Comparison of patients with HBV-related HCC with and without MASLD after liver transplantation

JHEP Reports 2026 Open access

Read full text
Authors: Huigang Li, Jinyan Chen, Chenghao Cao, Shusen Zheng, Xiao Xu, Di Lu
DOI: 10.1016/j.jhepr.2026.101877
Cited by: 1
References: 7

Abstract

We read with great interest the study by Ho et al. which demonstrated that hepatocellular carcinoma (HCC) patients with simple steatosis [metabolic dysfunction-associated steatotic liver disease (MASLD) without metabolic dysfunction-associated steatohepatitis (MASH)] had a significant survival advantage after hepatectomy, whereas progression to MASH negated this benefit[1]. Notably, in the subgroup of HBsAg-positive patients, the presence of MASLD or MASH did not significantly affect overall survival (OS) or recurrence-free survival (RFS).

Fields of Study & Subjects

Hepatitis B Virus Studies Organ Transplantation Techniques and Outcomes Hepatitis C virus research

Publication details

Journal / source
JHEP Reports
Publisher
Elsevier BV
Volume
8
Issue
8
Pages
101877–101877
Publication date
1 May 2026
Language
EN